Abeona therapeutics announces additional phase 3 viital™ study results for eb-101 presented at the international societies for investigative dermatology 2023 meeting

Cleveland, may 11, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced an oral presentation of additional data from the company's pivotal phase 3 viital™ study evaluating its investigational eb-101 for recessive dystrophic epidermolysis bullosa (rdeb). the data presentation occurred earlier today during the inaugural international societies for investigative dermatology (isid) meeting in tokyo, japan.
ABEO Ratings Summary
ABEO Quant Ranking